London, United Kingdom–(Newsfile Corp. – February 25, 2025) – Edison issues report on Accsys Technologies (AIM: AXS).
At its investor strategy day, Accsys set financial targets for the coming years, with a combined volume and revenue CAGR of 14% for FY25-30e for the plant in the Netherlands and the Accoya USA plant (60%/40% joint venture (JV)). Driven by increasing volumes, higher efficiency and operating leverage, Accsys targets adjusted group EBITDA to improve from €10.5m in FY25e (consensus) to €54m by FY30 (including its 60% share in the JV), exceeding our previous estimates. Accsys aims to bring down net debt to zero by FY30, which we think is achievable fuelled by increasing free cash flows. On higher long-term margins, our discounted cash flow indicates a value per share of 83p or €1.00 (up from €0.95 previously).
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website www.edisongroup.com
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242266
Toronto, Ontario--(Newsfile Corp. - June 19, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE:…
SAN FRANCISCO, June 19, 2025 (GLOBE NEWSWIRE) -- Commure, the fast-growing enterprise AI healthcare technology…
New studies confirm the clear benefit of early acute treatment, the consistent effectiveness of REN…
MONTREAL, June 19, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or…
PRESS RELEASE Memo Therapeutics AG to Present Interim Phase II Results of Potravitug for the…
FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="2px" width="2px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="76px" width="200px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
